Roth Capital Partners Initiates Coverage on Mydecine, With Buy Rating And C$3 Price Target
Roth Capital Partners is initiating coverage of Mydecine with a Buy rating and $3/share price target. Mydecine is the first to treat PTSD and smoking cessation with the natural form of psilocybin (MYCO – 001).
Full Report (Link)
![](https://assets-global.website-files.com/5ea1010ae2ce994c214a9e6f/60d266b62c40b409cff1f38c_2021-06-22%20(2).png)
Get the Headlines & Market Updates
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.